+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, Target Disease Indication, Route of Administration, Type of Therapy, and Geography- Product Image
Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, Target Disease Indication, Route of Administration, Type of Therapy, and Geography- Product Image
New

Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, Target Disease Indication, Route of Administration, Type of Therapy, and Geography

  • PDF Icon

    Report

  • September 2025
  • Region: Global
  • Roots Analysis
  • ID: 6171045
Description Jump to:

The global antisense oligonucleotides market valued at USD 2.5 billion in 2025, is anticipated to grow at a lucrative CAGR of 15% during the forecast period.

Antisense Oligonucleotides Market: Growth and Trends

Oligonucleotides are short single stranded DNA or RNA molecules, that comprise 15-20 nucleotide residues. In modern biopharmaceuticals, the applications of these oligonucleotides are vast, including (but not limited to) genetic testing, fundamental biomolecular research, and forensic analysis. Antisense oligonucleotides, a diverse class of oligonucleotides are short, single-stranded RNA / DNA molecules specifically binding to the target mRNA and have the ability to modify protein expression through a variety of mechanisms. 

Antisense therapeutics are considered to be one of the most promising agents for impairing protein production and blocking the function of the specific target gene of interest in the human genome. Presently, this mechanism forms the basis for many therapeutics being investigated in different stages of clinical trials for treatment of a variety of disorders, including oncological disorders, genetic diseases, hepatic diseases, respiratory disorders and infectious diseases. In fact, in the recent past, the oligonucleotide drug developers had also investigated the relevance of these interventions against the Coronavirus (COVID-19). Given the pace of innovation and developments in the antisense oligonucleotides market, we can expect antisense oligonucleotides to become a major therapeutic modality in the foreseen future.

Antisense Oligonucleotides Market: Key Insights

The report delves into the current state of the antisense oligonucleotides market and identifies potential growth opportunities within industry.

Some key findings from the report include:

  • Around 30 players from are presently engaged in evaluating the potential therapeutic benefits of antisense oligonucleotides for the treatment of a wide range of disease indications, worldwide.
  • The pipeline features 170+ candidate therapies in different stages of development, being evaluated either as monotherapies or in combination with other interventions; most of these products are administered parenterally.
  • Majority of the approved therapies and late-stage candidates are intended for the treatment of genetic disorders, neurological disorders and oncological disorders.
  • Given the advantages of antisense oligonucleotides, these interventions are primarily evaluated as monotherapy. Late-stage drugs being investigated as monotherapy include Tofersen and Pelacarsen.
  • Over 18,000 patients have been enrolled in clinical trial sites evaluating close to 70 antisense oligonucleotide-based therapy candidates.

  • Majority of the antisense oligonucleotide therapeutics are designed for subcutaneous administration; these can be self-administered by the patients using different drug delivery systems.
  • Several organizations have extended financial support to aid research efforts in this domain; currently, the focus, in terms of funds disbursed, is primarily in support of investigations of drugs for treating neurological conditions.
  • The number of grants awarded to stakeholders in this domain (in the US) has continuously increased in the past few years; more than 70% of the total amount was awarded for research projects.
  • The field has witnessed the involvement of various administering institutes of the NIH; of all the institutes, participation of the NINDS, NHLBI, and NCI has been relatively more prominent.
  • The rising interest in this field is reflected in the number of partnerships inked by the various stakeholders across different application areas.
  • Given that nearly 20 molecules are in the late stages of development, companies have primarily collaborated for product development and commercialization purposes.
  • Both established players and the new entrants have forged strategic partnerships in the recent past; these deals have primarily been inked for genetic and neurological disorders.
  • The future opportunity, in terms of revenues from the sales of marketed and late-stage therapies, is anticipated to be well distributed across different disease areas, types of molecules and key geographical regions.

  • The market is likely to witness steady growth over the coming decade; the opportunity will be dispersed across different generations, routes of administration and various types of therapies.

Report Scope:

Type of Antisense Molecule

  • DNA Molecules
  • RNA Molecules

Type of ASO Generation

  • First-Generation Products
  • Second-Generation Products
  • Third-Generation Products

Target Disease Indication

  • Amyotrophic Lateral Sclerosis
  • Duchenne Muscular Dystrophy
  • Familial Chylomicronemia Syndrome
  • Familial Partial Lipodystrophy
  • Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
  • Huntington’s Disease
  • Leber's Congenital Amaurosis
  • Spinal Muscular Atrophy

Route of Administration

  • Intrathecal Therapies
  • Intravenous Therapies
  • Intravitreal Therapies
  • Subcutaneous Therapies
  • Intraorifice Therapies

Type of Therapy

  • Combination Therapies
  • Monotherapies

Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Example Players in the Antisense Oligonucleotides Market Profiled in the Report Include:

  • Antisense Therapeutics
  • Biogen
  • Bio-Path Holdings
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
  • Wave Life Sciences 

Antisense Oligonucleotides Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global antisense oligonucleotides market, focusing on key market segments, including type of antisense molecule, type of ASO generation, target disease indication, route of administration, type of therapy and geography.
  • Market Landscape: A comprehensive evaluation of antisense oligonucleotide therapeutics, based on several relevant parameters, such as type of antisense molecule, ASO generation, phase of development of lead candidates, target genes, target disease indications, target therapeutic areas, route of administration and type of therapy. Additionally, a comprehensive evaluation of drug developers, based on several relevant parameters, such as year of establishment,  company size and location of headquarters.
  • Company Profiles: In-depth profiles of antisense oligonucleotide therapeutic developers, focusing on overview of the company, financial information (if available), product portfolio and recent developments and an informed future outlook.
  • Clinical Trial Analysis: An insightful analysis of clinical trials related to antisense oligonucleotide therapeutics, based on several parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target therapeutic area and target genes.
  • Grants Analysis: A comprehensive assessment of grants that have been awarded to research institutes for antisense oligonucleotide therapeutic projects, based on various relevant parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, type of recipient organizations and focus area. Additionally, a comprehensive assessment of grants focusing on geographical distribution of recipient organizations, popular therapeutic areas, popular funding institute centers, prominent program officers and popular recipient organizations.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the antisense oligonucleotide market, based on several parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships signed) and regional analysis.
  • Case Study: A detailed discussion on the oligonucleotide CMOs and purification service providers, highlighting information on the year of establishment, company size, scale of operation, location of headquarters and type of purification method used.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.5. COVID Impact / Related Factors
1.2.5.6. Market Access
1.2.5.7. Healthcare Policies
1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview on Oligonucleotides and Affiliated Medical Products
3.2.1. Types of Oligonucleotides
3.2.1.1. Antisense Oligonucleotides (ASOs)
3.2.1.2. Aptamers
3.2.1.3. miRNA
3.2.1.4. shRNA
3.2.1.5. siRNA
3.2.1.6. Other Oligonucleotides
3.3. Oligonucleotide Therapeutics
3.3.1. RNA-Interference Therapeutics
3.3.1.1. Components of RNA-Interference Therapeutics
3.3.1.2. Mechanism of RNA-Interference Therapeutics
3.3.2. Antisense Oligonucleotide Therapeutics
3.3.2.1. Mechanism of Antisense Oligonucleotide Therapeutics
3.3.2.2. Types of Antisense Oligonucleotide Therapeutics
3.4. Future Perspectives

4. ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antisense Oligonucleotide Therapeutics: Pipeline Review
4.2.1. Analysis by Type of Antisense Molecule
4.2.2. Analysis by ASO Generation
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Target Genes
4.2.5. Analysis by Target Indications
4.2.6. Analysis by Therapeutic Areas
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Type of Therapy
4.3. Antisense Oligonucleotide Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4. 3.3. Analysis by Location of Headquarters
4.4. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Antisense Therapeutics
5.2.1. Company Overview
5.2.2. Antisense Oligonucleotide Therapeutics Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Biogen
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Antisense Oligonucleotide Therapeutics Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Bio-Path Holdings
5.4.1. Company Overview
5.4.2. Antisense Oligonucleotide Therapeutics Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. Ionis Pharmaceuticals
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Antisense Oligonucleotide Therapeutics Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. ProQR Therapeutics
5.6.1. Company Overview
5.6.2. Antisense Oligonucleotide Therapeutics Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Sarepta Therapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Antisense Oligonucleotide Therapeutics Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Sterna Biologicals
5.8.1. Company Overview
5.8.2. Antisense Oligonucleotide Therapeutics Portfolio
5.8.3. Recent Developments and Future Outlook
5.9. Wave Life Sciences
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Antisense Oligonucleotide Therapeutics Portfolio
5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Antisense Oligonucleotide Therapeutics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Trial Recruitment Status
6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.5. Analysis by Study Design
6.3.6. Analysis by Type of Sponsor / Collaborator
6.3.7. Leading Players: Analysis by Number of Registered Trials
6.3.8. Word Cloud: Key Focus Areas
6.3.9. Analysis by Target Therapeutic Area
6.3.10. Analysis by Trial Registration Year and Target Gene
6.3.11. Popular Indications: Analysis by Number of Registered Trials
6.3.12. Popular Interventions: Analysis by Number of Registered Trials
6.3.13. Geographical Analysis by Number of Registered Trials
6.3.14. Geographical Analysis by Number of Patients Enrolled

7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antisense Oligonucleotide Therapeutics: Analysis of Academic Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Administering Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Administering Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Analysis by Study Section Involved
7.3.10. Analysis by Type of Recipient Organization
7.3.11. Word Cloud Analysis: Emerging Focus Areas
7.3.12. Geographical Distribution of Recipient Organizations
7.3.13. Popular Therapeutic Areas: Analysis by Number of Grants
7.3.14. Popular NIH Departments: Analysis by Number of Grants
7.3.15. Prominent Program Officers: Analysis by Number of Grants
7.3.16. Popular Recipient Organizations: Analysis by Number of Grants

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Antisense Oligonucleotide Therapeutics: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partnership and Generation of Antisense Molecule Involved
8.3.4. Analysis by Type of Partnership and Target Therapeutic Area
8.3.5. Analysis by Year of Partnership and Type of Partner
8.3.6. Analysis by Type of Partnership and Type of Partner
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Antisense Oligonucleotide Therapeutics Market, Till 2035
9.4. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Individual Product Sales Forecasts
9.4.1. Alicaforsen (Atlantic Healthcare)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast
9.4.2. Eteplirsen (Sarepta Therapeutics)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast
9.4.3. Golodirsen (Sarepta Therapeutics)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast
9.4.4. Inotersen (Ionis Pharmaceuticals)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast
9.4.5. Sepofarsen (ProQR Therapeutics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast
9.4.6. Tofersen (Biogen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast
9.4.7. Tominersen (Roche)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast
9.4.8. Viltolarsen (Nippon Shinyaku)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast
9.4.9. Volanesorsen (Ionis Pharmaceuticals)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast
9.5. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Antisense Molecule
9.5.1. Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, Till 2035
9.5.2. Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, Till 2035
9.6. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by ASO Generation
9.6.1. Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, Till 2035
9.6.2. Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, Till 2035
9.6.3. Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, Till 2035
9.7. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Target Disease Indication
9.7.1. Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, Till 2035
9.7.2. Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, Till 2035
9.7.3. Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, Till 2035
9.7.4. Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, Till 2035
9.7.5. Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, Till 2035
9.7.6. Global Antisense Oligonucleotide Therapeutics Market for Huntington’s Disease, Till 2035
9.7.7. Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, Till 2035
9.7.8. Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, Till 2035
9.7.9. Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, Till 2035
9.8. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Route of Administration
9.8.1. Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, Till 2035
9.8.2. Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, Till 2035
9.8.3. Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, Till 2035
9.8.4. Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, Till 2035
9.8.5. Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, Till 2035
9.9. Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Therapy
9.9.1. Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies Till 2035
9.9.2. Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, Till 2035
9.10. Global Antisense Oligonucleotide Market, Till 2035: Geographical Distribution
9.10.1. Antisense Oligonucleotide Market in the US, Till 2035
9.10.2. Antisense Oligonucleotide Market in Canada, Till 2035
9.10.3. Antisense Oligonucleotide Market in the UK, Till 2035
9.10.4. Antisense Oligonucleotide Market in Germany, Till 2035
9.10.5. Antisense Oligonucleotide Market in France, Till 2035
9.10.6. Antisense Oligonucleotide Market in Italy, Till 2035
9.10.7. Antisense Oligonucleotide Market in Spain, Till 2035
9.10.8. Antisense Oligonucleotide Market in Australia, Till 2035
9.10.9. Antisense Oligonucleotide Market in Japan, Till 2035
9.10.10. Antisense Oligonucleotide Market in Korea, Till 2035
9.10.11. Antisense Oligonucleotide Market in Brazil, Till 2035
9.10.12. Antisense Oligonucleotide Market in Israel, Till 2035

10. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERS AND PURIFICATION SERVICES
10.1. Chapter Overview
10.2. List of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Scale of Operation
10.2.4. Analysis by Location of Headquarters
10.2.5. Analysis by Type of Purification Method Used
10.3. List of Oligonucleotide Manufacturers Focused on Therapeutic Applications
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Location of Headquarters
10.3.5. Analysis by Type of Purification Method Used

11. CONCLUDING REMARKS12. APPENDIX 1: TABULATED DATA13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Classification of Oligonucleotides
Figure 3.2 Key Components of RNA interference
Figure 3.3 Mechanism of RNA interference
Figure 3.4 Key Features of Antisense Oligonucleotides
Figure 3.5 Mechanism of Antisense Oligonucleotides
Figure 4.1 Antisense Oligonucleotide Therapeutics: Distribution by Type of Antisense Molecule
Figure 4.2 Antisense Oligonucleotide Therapeutics: Distribution by ASO Generation
Figure 4.3 Antisense Oligonucleotide Therapeutics: Distribution by Phase of Development
Figure 4.4 Antisense Oligonucleotide Therapeutics: Distribution by Target Genes
Figure 4.5 Antisense Oligonucleotide Therapeutics: Distribution by Target Indications
Figure 4.6 Antisense Oligonucleotide Therapeutics: Distribution by Therapeutic Areas
Figure 4.7 Antisense Oligonucleotide Therapeutics: Distribution by Route of Administration
Figure 4.8 Antisense Oligonucleotide Therapeutics: Distribution by Type of Therapy
Figure 4.9 Antisense Oligonucleotide Therapeutic Developers: Distribution by Year of Establishment
Figure 4.10 Antisense Oligonucleotide Therapeutic Developers: Distribution by Company Size
Figure 4.11 Antisense Oligonucleotide Therapeutic Developers: Distribution by Location of Headquarters
Figure 4.12 Grid Analysis: Distribution by Phase of Development of Therapeutics, Company Size and Location of Headquarters
Figure 5.1 Biogen: Annual Revenues, Since 2015 (USD Million)
Figure 5.2 Ionis Pharmaceuticals: Annual Revenues, Since 2015 (USD Million)
Figure 5.3 Sarepta Therapeutics: Annual Revenues, Since 2015 (USD Million)
Figure 5.4 Wave Life Sciences: Annual Revenues, Since 2015 (USD Million)
Figure 6.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 6.5 Clinical Trial Analysis: Distribution by Study Design
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.7 Leading Players: Distribution by Number of Registered Trials
Figure 6.8 Word Cloud: Key Focus Areas
Figure 6.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Popular Interventions: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2017
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), Since 2017
Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Grant Analysis: Distribution by Study Section Involved
Figure 7.10 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.11 Word Cloud Analysis: Emerging Focus Areas
Figure 7.12 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 7.13 Popular Therapeutic Areas: Distribution by Number of Grants
Figure 7.14 Popular NIH Departments: Distribution by Number of Grants
Figure 7.15 Prominent Program Officers: Distribution by Number of Grants
Figure 7.16 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Antisense Molecule Involved
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Target Therapeutic Area
Figure 8.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.7 Most Active Players: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Global Antisense Oligonucleotide Therapeutics Market, Till 2035 (USD Million)
Figure 9.2 Alicaforsen: Sales Forecast, Till 2035 (USD Million)
Figure 9.3 Eteplirsen: Sales Forecast, Till 2035 (USD Million)
Figure 9.4 Golodirsen: Sales Forecast, Till 2035 (USD Million)
Figure 9.5 Inotersen: Sales Forecast, Till 2035 (USD Million)
Figure 9.6 Sepofarsen: Sales Forecast, Till 2035 (USD Million)
Figure 9.7 Tofersen: Sales Forecast, Till 2035 (USD Million)
Figure 9.8 Tominersen: Sales Forecast, Till 2035 (USD Million)
Figure 9.9 Viltolarsen: Sales Forecast, Till 2035 (USD Million)
Figure 9.10 Volanesorsen: Sales Forecast, Till 2035 (USD Million)
Figure 9.11 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Antisense Molecule (USD Million)
Figure 9.12 Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, Till 2035 (USD Million)
Figure 9.13 Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, Till 2035 (USD Million)
Figure 9.14 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by ASO Generation (USD Million)
Figure 9.15 Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, Till 2035 (USD Million)
Figure 9.16 Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, Till 2035 (USD Million)
Figure 9.17 Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, Till 2035 (USD Million)
Figure 9.18 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Target Disease Indication (USD Million)
Figure 9.19 Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, Till 2035 (USD Million)
Figure 9.20 Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, Till 2035 (USD Million)
Figure 9.21 Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, Till 2035 (USD Million)
Figure 9.22 Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, Till 2035 (USD Million)
Figure 9.23 Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, Till 2035 (USD Million)
Figure 9.24 Global Antisense Oligonucleotide Therapeutics Market for Huntington’s Disease, Till 2035 (USD Million)
Figure 9.25 Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, Till 2035 (USD Million)
Figure 9.26 Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, Till 2035 (USD Million)
Figure 9.27 Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, Till 2035 (USD Million)
Figure 9.28 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Route of Administration (USD Million)
Figure 9.29 Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, Till 2035 (USD Million)
Figure 9.30 Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, Till 2035 (USD Million)
Figure 9.31 Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, Till 2035 (USD Million)
Figure 9.32 Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, Till 2035 (USD Million)
Figure 9.33 Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, Till 2035 (USD Million)
Figure 9.34 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Therapy (USD Million)
Figure 9.35 Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies Till 2035 (USD Million)
Figure 9.36 Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, Till 2035 (USD Million)
Figure 9.37 Global Antisense Oligonucleotide Market, Till 2035: Distribution by Geography (USD Million)
Figure 9.38 Antisense Oligonucleotide Market in the US, Till 2035 (USD Million)
Figure 9.39 Antisense Oligonucleotide Market in Canada, Till 2035 (USD Million)
Figure 9.40 Antisense Oligonucleotide Market in the UK, Till 2035 (USD Million)
Figure 9.41 Antisense Oligonucleotide Market in Germany, Till 2035 (USD Million)
Figure 9.42 Antisense Oligonucleotide Market in France, Till 2035 (USD Million)
Figure 9.43 Antisense Oligonucleotide Market in Italy, Till 2035 (USD Million)
Figure 9.44 Antisense Oligonucleotide Market in Spain, Till 2035 (USD Million)
Figure 9.45 Antisense Oligonucleotide Market in Australia, Till 2035 (USD Million)
Figure 9.46 Antisense Oligonucleotide Market in Japan, Till 2035 (USD Million)
Figure 9.47 Antisense Oligonucleotide Market in Korea, Till 2035 (USD Million)
Figure 9.48 Antisense Oligonucleotide Market in Brazil, Till 2035 (USD Million)
Figure 9.49 Antisense Oligonucleotide Market in Israel, Till 2035 (USD Million)
Figure 10.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 10.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 10.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 10.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
Figure 10.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method Used
Figure 10.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 10.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 10.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 10.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters
Figure 10.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method Used
LIST OF TABLES
Table 4.1 Antisense Oligonucleotide Therapeutics: List of Drugs
Table 4.2 Antisense Oligonucleotide Therapeutics: List of Developers
Table 5.1 Antisense Oligonucleotide Therapeutics: List of Companies Profiled
Table 5.2 Antisense Therapeutics: Company Snapshot
Table 5.3 Drug Profile: ATL1102
Table 5.4 Drug Profile: ATL1103
Table 5.5 Antisense Therapeutics: Recent Developments and Future Outlook
Table 5.6 Biogen: Company Snapshot
Table 5.7 Drug Profile: Tofersen
Table 5.8 Drug Profile: ION541
Table 5.9 Biogen: Recent Developments and Future Outlook
Table 5.10 Bio-Path Holdings: Company Snapshot
Table 5.11 Drug Profile: Prexigebersen
Table 5.12 Drug Profile: BP1002
Table 5.13 Drug Profile: BP1003
Table 5.14 Bio-Path Holdings: Recent Developments and Future Outlook
Table 5.15 Ionis Pharmaceuticals: Company Snapshot
Table 5.16 Drug Profile: Spinraza®
Table 5.17 Drug Profile: Tegsedi®
Table 5.18 Drug Profile: Waylivra®
Table 5.19 Drug Profile: AKCEA-APOCIII-LRx
Table 5.20 Drug Profile: IONIS-PKK-LRx
Table 5.21 Drug Profile: IONIS-PKK-Rx
Table 5.22 Drug Profile: IONIS-ENAC-2.5Rx
Table 5.23 Drug Profile: IONIS-FB-LRx
Table 5.24 Drug Profile: IONIS-AGT-LRx
Table 5.25 Drug Profile: AKCEA-TTR-LRx
Table 5.26 Drug Profile: IONIS-GHR-LRx
Table 5.27 Drug Profile: ION253
Table 5.28 Drug Profile: IONIS-TMPRSS6-LRx
Table 5.29 Drug Profile: ION736
Table 5.30 Drug Profile: IONIS-AR-2.5Rx
Table 5.31 Drug Profile: ION224
Table 5.32 Drug Profile: ISIS-FGFR4RX
Table 5.33 Drug Profile: ISIS-GCCRRx
Table 5.34 Drug Profile: IONIS-GCGRRx
Table 5.35 Drug Profile: IONIS-HBV-LRx
Table 5.36 Drug Profile: ION251
Table 5.37 Drug Profile: ION 449
Table 5.38 Drug Profile: BIIB078
Table 5.39 Drug Profile: BIIB094
Table 5.40 Drug Profile: BIIB101
Table 5.41 Drug Profile: ISIS-EIF4ERx
Table 5.42 Drug Profile: BIIB080
Table 5.43 Drug Profile: ION663
Table 5.44 Drug Profile: ION674
Table 5.45 Drug Profile: ION537
Table 5.46 Drug Profile: ION929
Table 5.47 Drug Profile: ION363
Table 5.48 Drug Profile: ION373
Table 5.49 Drug Profile: ION283
Table 5.50 Drug Profile: ION260
Table 5.51 Drug Profile: ION581
Table 5.52 Drug Profile: ION716
Table 5.53 Drug Profile: ION904
Table 5.54 Drug Profile: ION547
Table 5.55 Ionis Pharmaceuticals: Recent Developments and Future Outlook
Table 5.56 ProQR Therapeutics: Company Snapshot
Table 5.57 Drug Profile: Sepofarsen
Table 5.58 Drug Profile: QR-421a
Table 5.59 Drug Profile: QR-1123
Table 5.60 Drug Profile: QR-411
Table 5.61 Drug Profile: QR-504a
Table 5.62 Drug Profile: QRX-704
Table 5.63 Drug Profile: QR-1011
Table 5.64 Drug Profile: QRX-461
Table 5.65 Drug Profile: QRX-136
Table 5.66 Drug Profile: QRX-1204
Table 5.67 ProQR Therapeutics: Recent Developments and Future Outlook
Table 5.68 Sarepta Therapeutics: Company Snapshot
Table 5.69 Drug Profile: Exondys 51
Table 5.70 Drug Profile: Vyondys 53
Table 5.71 Drug Profile: Amondys 45
Table 5.72 Drug Profile: SRP-5051
Table 5.73 Drug Profile: Exon 52
Table 5.74 Drug Profile: Exon 43
Table 5.75 Drug Profile: Exon 44
Table 5.76 Drug Profile: Exon 50
Table 5.77 Drug Profile: Exon 55
Table 5.78 Drug Profile: SRP-5052
Table 5.79 Drug Profile: SRP-5053
Table 5.80 Drug Profile: SRP-5044
Table 5.81 Drug Profile: SRP-5045
Table 5.82 Drug Profile: SRP-5050
Table 5.83 Sarepta Therapeutics: Recent Developments and Future Outlook
Table 5.84 Sterna Biologicals: Company Snapshot
Table 5.85 Drug Profile: SB010
Table 5.86 Drug Profile: SB011
Table 5.87 Drug Profile: SB012
Table 5.88 Sterna Biologicals: Recent Developments and Future Outlook
Table 5.89 Wave Life Sciences: Company Snapshot
Table 5.90 Drug Profile: WVE-120102
Table 5.91 Drug Profile: Suvodirsen
Table 5.92 Drug Profile: WVE-004
Table 5.93 Drug Profile: WVE-003
Table 5.94 Drug Profile: WVE-N531
Table 5.95 Drug Profile: Undisclosed Drug 1
Table 5.96 Drug Profile: Undisclosed Drug 2
Table 5.97 Drug Profile: Undisclosed Drug 3
Table 5.98 Drug Profile: Undisclosed Drug 4
Table 5.99 Drug Profile: Undisclosed Drug 5
Table 5.100 Drug Profile: Undisclosed Drug 6
Table 5.101 Wave Life Sciences: Recent Developments and Future Outlook
Table 8.1 Antisense Oligonucleotide Therapeutics: List of Partnerships and Collaborations
Table 9.1 Antisense Oligonucleotide Therapeutics: Summary of the Competitive Insights
Table 10.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 10.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 12.1 Antisense Oligonucleotide Therapeutics: Distribution by Type of Antisense Molecule
Table 12.2 Antisense Oligonucleotide Therapeutics: Distribution by ASO Generation
Table 12.3 Antisense Oligonucleotide Therapeutics: Distribution by Phase of Development
Table 12.4 Antisense Oligonucleotide Therapeutics: Distribution by Target Genes
Table 12.5 Antisense Oligonucleotide Therapeutics: Distribution by Target Indications
Table 12.6 Antisense Oligonucleotide Therapeutics: Distribution by Therapeutic Areas
Table 12.7 Antisense Oligonucleotide Therapeutics: Distribution by Route of Administration
Table 12.8 Antisense Oligonucleotide Therapeutics: Distribution by Type of Therapy
Table 12.9 Antisense Oligonucleotide Therapeutic Developers: Distribution by Year of Establishment
Table 12.10 Antisense Oligonucleotide Therapeutic Developers: Distribution by Company Size
Table 12.11 Antisense Oligonucleotide Therapeutic Developers: Distribution by Location of Headquarters
Table 12.12 Biogen: Annual Revenues, Since 2015 (USD Million)
Table 12.13 Ionis Pharmaceuticals: Annual Revenues, Since 2015 (USD Million)
Table 12.14 Sarepta Therapeutics: Annual Revenues, Since 2015 (USD Million)
Table 12.15 Wave Life Sciences: Annual Revenues, Since 2015 (USD Million)
Table 12.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Table 12.17 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.18 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 12.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 12.20 Clinical Trial Analysis: Distribution by Study Design
Table 12.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.22 Leading Players: Distribution by Number of Registered Trials
Table 12.23 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 12.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Table 12.25 Popular Indications: Distribution by Number of Registered Trials
Table 12.26 Popular Interventions: Distribution by Number of Registered Trials
Table 12.27 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 12.28 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 12.29 Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2017
Table 12.30 Grant Analysis: Cumulative Distribution by Amount Awarded, Since 2017 (USD Million)
Table 12.31 Grant Analysis: Distribution by Administering Institute Center
Table 12.32 Grant Analysis: Distribution by Support Period
Table 12.33 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 12.34 Grant Analysis: Distribution by Type of Grant Application
Table 12.35 Grant Analysis: Distribution by Purpose of Grant Award
Table 12.36 Grant Analysis: Distribution by Activity Code
Table 12.37 Grant Analysis: Distribution by Study Section Involved
Table 12.38 Grant Analysis: Distribution by Type of Recipient Organization
Table 12.39 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 12.40 Popular Therapeutic Areas: Distribution by Number of Grants
Table 12.41 Popular NIH Departments: Distribution by Number of Grants
Table 12.42 Prominent Program Officers: Distribution by Number of Grants
Table 12.43 Popular Recipient Organizations: Distribution by Number of Grants
Table 12.44 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2016
Table 12.45 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.46 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Antisense Molecule Involved
Table 12.47 Partnerships and Collaborations: Distribution by Type of Partnership and Target Therapeutic Area
Table 12.48 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 12.49 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 12.50 Most Active Players: Distribution by Number of Partnerships
Table 12.51 Partnerships and Collaborations: Regional Distribution
Table 12.52 Global Antisense Oligonucleotide Therapeutics Market, Till 2035 (USD Million)
Table 12.53 Alicaforsen: Sales Forecast, Till 2035 (USD Million)
Table 12.54 Eteplirsen: Sales Forecast, Till 2035 (USD Million)
Table 12.55 Golodirsen: Sales Forecast, Till 2035 (USD Million)
Table 12.56 Inotersen: Sales Forecast, Till 2035 (USD Million)
Table 12.57 Sepofarsen: Sales Forecast, Till 2035 (USD Million)
Table 12.58 Tofersen: Sales Forecast, Till 2035 (USD Million)
Table 12.59 Tominersen: Sales Forecast, Till 2035 (USD Million)
Table 12.60 Viltolarsen: Sales Forecast, Till 2035 (USD Million)
Table 12.61 Volanesorsen: Sales Forecast, Till 2035 (USD Million)
Table 12.62 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Antisense Molecule (USD Million)
Table 12.63 Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, Till 2035 (USD Million)
Table 12.64 Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, Till 2035 (USD Million)
Table 12.65 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by ASO Generation (USD Million)
Table 12.66 Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, Till 2035 (USD Million)
Table 12.67 Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, Till 2035 (USD Million)
Table 12.68 Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, Till 2035 (USD Million)
Table 12.69 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Target Disease Indication (USD Million)
Table 12.70 Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, Till 2035 (USD Million)
Table 12.71 Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, Till 2035 (USD Million)
Table 12.72 Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, Till 2035 (USD Million)
Table 12.73 Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, Till 2035 (USD Million)
Table 12.74 Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, Till 2035 (USD Million)
Table 12.75 Global Antisense Oligonucleotide Therapeutics Market for Huntington’s Disease, Till 2035 (USD Million)
Table 12.76 Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, Till 2035 (USD Million)
Table 12.77 Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, Till 2035 (USD Million)
Table 12.78 Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, Till 2035 (USD Million)
Table 12.79 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Route of Administration (USD Million)
Table 12.80 Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, Till 2035 (USD Million)
Table 12.81 Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, Till 2035 (USD Million)
Table 12.82 Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, Till 2035 (USD Million)
Table 12.83 Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, Till 2035 (USD Million)
Table 12.84 Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, Till 2035 (USD Million)
Table 12.85 Global Antisense Oligonucleotide Therapeutics Market, Till 2035: Distribution by Type of Therapy (USD Million)
Table 12.86 Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies Till 2035 (USD Million)
Table 12.87 Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, Till 2035 (USD Million)
Table 12.88 Global Antisense Oligonucleotide Market, Till 2035: Distribution by Geography (USD Million)
Table 12.89 Antisense Oligonucleotide Market in the US, Till 2035 (USD Million)
Table 12.90 Antisense Oligonucleotide Market in Canada, Till 2035 (USD Million)
Table 12.91 Antisense Oligonucleotide Market in the UK, Till 2035 (USD Million)
Table 12.92 Antisense Oligonucleotide Market in Germany, Till 2035 (USD Million)
Table 12.93 Antisense Oligonucleotide Market in France, Till 2035 (USD Million)
Table 12.94 Antisense Oligonucleotide Market in Italy, Till 2035 (USD Million)
Table 12.95 Antisense Oligonucleotide Market in Spain, Till 2035 (USD Million)
Table 12.96 Antisense Oligonucleotide Market in Australia, Till 2035 (USD Million)
Table 12.97 Antisense Oligonucleotide Market in Japan, Till 2035 (USD Million)
Table 12.98 Antisense Oligonucleotide Market in Korea, Till 2035 (USD Million)
Table 12.99 Antisense Oligonucleotide Market in Brazil, Till 2035 (USD Million)
Table 12.100 Antisense Oligonucleotide Market in Israel, Till 2035 (USD Million)
Table 12.101 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 12.102 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 12.103 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 12.104 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
Table 12.105 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method Used
Table 12.106 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Table 12.107 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Table 12.108 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Table 12.109 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters
Table 12.110 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method Used

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Antisense Therapeutics
  • Biogen
  • Bio-Path Holdings
  • Ionis Pharmaceuticals
  • ProQR Therapeutics
  • Sarepta Therapeutics
  • Sterna Biologicals
  • Wave Life Sciences 

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2025 - Product Image

Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2025

  • Drug Pipelines
  • 280 Pages
  • Global
From
Antisense Oligonucleotide Therapeutics Market - Global Forecast 2025-2030 - Product Image

Antisense Oligonucleotide Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033 - Product Image

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2023-2033

  • Report
  • 286 Pages
  • Global
From
Small Nucleic Acid Therapies Market - Global Forecast 2025-2030 - Product Image

Small Nucleic Acid Therapies Market - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Innovation Insights: Anti-sense Oligonucleotides - Product Image

Innovation Insights: Anti-sense Oligonucleotides

  • Report
  • 51 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.